CJ-002

CJ-002 is a small molecule phosphodiesterase type 5 (PDE5) inhibitor developed by Guangdong Xijie Pharmaceutical. It is formulated as a nanocrystal orally disintegrating tablet (ODT), which is classified as a Class 2 improved new drug in China. By inhibiting PDE5, the drug prevents the degradation of cyclic guanosine monophosphate (cGMP), thereby promoting smooth muscle relaxation and vasodilation. CJ-002 is primarily being developed for the treatment of erectile dysfunction (ED), erectile dysfunction comorbid with benign prostatic hyperplasia (BPH), and pulmonary arterial hypertension (PAH). The nanocrystal ODT formulation is designed to enhance bioavailability and provide a more convenient administration route compared to traditional oral tablets, potentially offering a faster onset of action.

Other names

tadalafil nanocrystal orally disintegrating tablet